you are here: HomeNewsIndia

Coronavirus mutant strains not behind surge in cases in Maharashtra, Kerala: Government

There is no direct relation between the recent surge in COVID-19 cases in Maharashtra and some other states with the mutant virus strains N440K and E484Q, stated Dr Balram Bhargava, Director General, ICMR.

February 24, 2021 / 08:32 AM IST
People wearing protective face masks wait in queues to buy train tickets at the Chhatrapati Shivaji Maharaj Terminus railway station in Mumbai, India. (Representative image: Reuters)

People wearing protective face masks wait in queues to buy train tickets at the Chhatrapati Shivaji Maharaj Terminus railway station in Mumbai, India. (Representative image: Reuters)

There is no direct relation between the recent surge in COVID-19 cases in Maharashtra and some other states, and the mutant virus strains -- N440K and E484Q -- of SARS-CoV-2, the Centre said on February 23.

Addressing a press conference, NITI Aayog Member (Health) VK Paul said that 187 people have tested positive for the UK strain of SARS-CoV-2 in the country so far, while six have been detected with the South Africa variant. Also, one person has been detected with the Brazil variant so far.

Also, the N440K and E484Q variants of SARS-CoV-2 have been detected in Maharashtra, Kerala and Telangana. Also, three other mutated strains -- one each from the UK, South Africa and Brazil are already present in the country. But there is no reason for us to believe presently, on the basis of scientific information, that they are responsible for the upsurge of the outbreak in some districts of Maharashtra and Kerala, Paul said.

Two states, Kerala and Maharashtra, account for 75 percent of total active COVID-19 cases in the country.

Follow our LIVE blog for the latest updates of the novel coronavirus pandemic


COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more

Reporting only detection does not lead to any attribution for a phenomenon on the ground because to relate the occurrence of a virus mutation to change in disease pattern, other epidemiological information and clinical information has to be linked to these mutants, Paul said, adding, because otherwise these (mutations) keep happening but they have no influence on the pandemic.

He said the behaviour of mutations is being constantly and closely watched in the country and 3,500 samples have been sequenced so far.

When we are doing sequencing, we are looking for any abnormal shift in the virus character. We have been watching the mutants.

Today, based on the information and as analyzed and understood by a very eminent scientific advisory group of Indian SARS-CoV-2 Genomics Consortium (INSACOG), we would like to underline the fact that we do not see attribution of mutant strains to the upsurge of the infection being seen in some districts. But this is work in progress. We will continue to watch the situation with full responsibility, Paul said.

The INSACOG was established in December end for laboratory and epidemiological surveillance of circulating strains of SARS-CoV-2 in the country.

Stating that a large proportion of the population is still vulnerable, Paul stressed that COVID appropriate behaviour like wearing masks, maintaining social distancing, hand washing and not going to mass gatherings should be followed.

Also read | Over 1.61 lakh people receive coronavirus vaccine in India on February 23

"There is no direct relation between the recent surge in COVID-19 cases in Maharashtra and some other states with the mutant virus strains N440K and E484Q," stated Dr Balram Bhargava, Director General, ICMR.

He further clarified that these two virus strains have been detected in other countries too and are not specific to India.

Moreover, they have been found earlier in some states in India.

The E484Q strain was earlier detected in four sequences in Maharashtra as early as March and July 2020.

The N440K mutation has been reported on 13 different occasions between May and September 2020 in Telangana, Andhra Pradesh and Assam. The current upsurge in Maharashtra cannot be attributed to the currently discussed point mutations, he said.

However, as further scientific evidence emerges, it shall be duly shared, he added.

The health Ministry has sent central teams to some states and will be sending teams to some more states which have shown a surge in COVID cases recently, Union Health Secretary Rajesh Bhushan said.

Maharashtra, he said is showing a daily surge in COVID-19 cases. Kerala is showing an incremental decline, but the daily cases in absolute numbers is still high over there. Punjab, with its daily increase in cases, is also a cause of worry.

Chhattisgarh and Madhya Pradesh are also showing an increase in daily cases. Jammu and Kashmir had a sudden spike and then showed a reduction in the number of daily cases. A central team of epidemiologists and public health experts will also visit Jammu and Kashmir, Bhushan said.

These central teams analyse the reasons for spike in cases and then hold discussions with the chief secretary and health secretary of the visited states to share their findings and advise on the steps to be taken to contain this surge.

The cumulative number of COVID-19 vaccine doses administered to healthcare and frontline workers has reached1,19,07,392till Tuesday 6 pm, the Union Health Ministry said.

These include64,71,047healthcareworkers (HCWs) who have taken the first dose and13,21,635HCWs who have taken the second dose, along with41,14,710frontline workers (FLWs) taking the first dose .

Union Health Secretary Rajesh Bhushan said that 11 states and UTs, including Karnataka, Ladakh, Tamil Nadu, Telangana, Delhi, Punjab and Chandigarh have administered the first dose to less than 60 per cent of the HCWs.

Ten states and UTs including Tripura, Kerala, Gujarat, Telangana, Ladakh and Himachal Pradesh have administered second dose to more than 75 per cent of the eligible HCWs.

On the other hand, ten states and UTs including Assam, Tamil Nadu, Chandigarh and Goa have vaccinated less than 25 per cent of FLWs.

In reply to a media query, Bushan said vaccination of senior citizens and people with co-morbidities will be started soon.

A decision on the dosing interval of Covishield may be expected from the National Technical Advisory Group on Immunization (NTAGI) anytime, said Paul in reply to another query.

Follow our full coverage on COVID-19 here.
first published: Feb 23, 2021 09:51 pm

stay updated

Get Daily News on your Browser